Difference between revisions of "Team:Queens Canada"
m |
m |
||
| (20 intermediate revisions by 2 users not shown) | |||
| Line 35: | Line 35: | ||
<div class="col-lg-6"> | <div class="col-lg-6"> | ||
<div class="video-intro-text"> | <div class="video-intro-text"> | ||
| − | <h3>An estimated 2 million</h3> | + | <h3>An estimated 2 million Canadians</h3> |
| − | <h4> | + | <h4>suffer from Chronic Kidney Disease <br>each year.</h4> |
<h5> | <h5> | ||
QGEM’s biosensor monitors in vivo levels of phosphate, potassium, parathyroid hormone, FGF23 and | QGEM’s biosensor monitors in vivo levels of phosphate, potassium, parathyroid hormone, FGF23 and | ||
| Line 57: | Line 57: | ||
<div class="intro-video-screen"> | <div class="intro-video-screen"> | ||
<video class = actual-intro-video controls> | <video class = actual-intro-video controls> | ||
| − | <source src = "https://static.igem.org/mediawiki/2020/ | + | <source src = "https://static.igem.org/mediawiki/2020/4/4f/T--Queens_Canada--homepage-video-2.mp4" type = video/mp4> |
</video> | </video> | ||
| + | <a href = https://static.igem.org/mediawiki/2020/e/eb/T--Queens_Canada--Promo-Transcript.pdf target = _blank><button onclick = pauseHomeVideo() class = primary-button id = home-transcript-btn>Transcript</button></a> | ||
<i class="fa fa-times close" aria-hidden="true" onclick = "toggle();"></i> | <i class="fa fa-times close" aria-hidden="true" onclick = "toggle();"></i> | ||
</div> | </div> | ||
| Line 97: | Line 98: | ||
<div id = home-interactive> | <div id = home-interactive> | ||
| − | + | <section class="page-content" style="background-color: #33658a;"> | |
| − | <div class = | + | <div class = "container" > |
| − | < | + | <div class="section-title"> |
| + | <h3 style="color: #fff; text-align: center;">So how big of an <span style="color: #dbbadd">issue</span> is this?</h3> | ||
| + | <h5 style="color: #fff; text-align: center;">Guess how much phosphate is in your favourite foods <br>Click below to find out...<br><br></h3> | ||
| + | </div> | ||
</div> | </div> | ||
| − | + | </section> | |
<div class="container" id = outer-food-wrapper> | <div class="container" id = outer-food-wrapper> | ||
<div class="row" id = food-wrapper> | <div class="row" id = food-wrapper> | ||
| Line 202: | Line 206: | ||
<section class = home-abstract> | <section class = home-abstract> | ||
| + | |||
<div class="section-paragraph"> | <div class="section-paragraph"> | ||
| − | <p style="display: block; text-align: left; font-weight: 400; font-size: 1.1em; line-height: 1.6;"> | + | <p style="display: block; text-align: left; font-weight: 400; font-size: 1.1em; line-height: 1.6;">Team Queen's Canada will be designing a novel transdermal biosensor for point-of-care diagnostic quantification of phosphate, potassium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) for chronic kidney disease (CKD) patients. Knowledge of the concentration of these analytes is critical for guiding effective treatments and improving patient outcomes. We will generate genetically encoded Förster resonance energy transfer (FRET) sensors by fusing the N- and C-termini of phosphate-binding protein (PBP), potassium-binding protein (KBP), PTH 1 receptor (PTH1R), and α-Klotho to fluorescent proteins (FPs). To quantify physiologically relevant levels of phosphate, potassium, PTH and FGF23, highly optimized mNeonGreen and mCherry will be used as the FPs. Site-directed mutagenesis will be employed on protein-fluorophore constructs to add a Cysteine residue, to which a glutamate (E)/ lysine (K) coiled-coil system will be added to immobilize the construct onto a microfluidic surface. Through frequent monitoring and early disease detection, we hope to revolutionize CKD diagnostics. |
| − | + | ||
</p> | </p> | ||
</section> | </section> | ||
| − | |||
| − | |||
| − | |||
</div> | </div> | ||
Latest revision as of 02:23, 28 October 2020
Meet Velcrion.
QGEM’s biosensor monitors in vivo levels of phosphate, potassium, parathyroid hormone, FGF23 and glucose to better treat CKD patients
Together - high Phosphate, Potassium, Parathyroid Hormone, FGF23 and glucose levels can potentially pose a life-threatening risk to CKD patients.
Frequent monitoring of interstitial fluid in CKD patients can prove to be lifesaving, but in Canada blood is taken only every 6 weeks!
We want to change that.
Guess how much phosphate is in your favourite foods
Sausage McGriddle©
There are 652.2mg of phosphate in a Sausage McGriddle©
Tim Horton's© Muffin
There are 203.0 mg of phosphate in a Tim Horton's© Muffin
Subway Chicken Teriyaki©
There are 570.7 mg of phosphate in a Chicken Teriyaki sandwich from Subway©
Team Queen's Canada will be designing a novel transdermal biosensor for point-of-care diagnostic quantification of phosphate, potassium, parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) for chronic kidney disease (CKD) patients. Knowledge of the concentration of these analytes is critical for guiding effective treatments and improving patient outcomes. We will generate genetically encoded Förster resonance energy transfer (FRET) sensors by fusing the N- and C-termini of phosphate-binding protein (PBP), potassium-binding protein (KBP), PTH 1 receptor (PTH1R), and α-Klotho to fluorescent proteins (FPs). To quantify physiologically relevant levels of phosphate, potassium, PTH and FGF23, highly optimized mNeonGreen and mCherry will be used as the FPs. Site-directed mutagenesis will be employed on protein-fluorophore constructs to add a Cysteine residue, to which a glutamate (E)/ lysine (K) coiled-coil system will be added to immobilize the construct onto a microfluidic surface. Through frequent monitoring and early disease detection, we hope to revolutionize CKD diagnostics.